ETS translocation variant 1 (ETV1) (ETV1)

ETS translocation variant 1 (ETV1) is a member of the PEA3 subfamily within the ETS (E-twenty-six) family of transcription factors, primarily functioning as a sequence-specific DNA-binding protein that regulates genes involved in cell growth, differentiation, and migration (UniProt P50549; GeneCards). In normal physiology, ETV1 is critical for the development of the cardiac ventricular conduction system, sensory-motor circuitry in the spinal cord, and the interstitial cells of Cajal in the gastrointestinal tract (NIH.gov; Atlas of Genetics and Cytogenetics in Oncology and Haematology). Pathologically, ETV1 acts as a potent oncogene and is frequently dysregulated via chromosomal translocations in prostate cancer and Ewing sarcoma, gene amplification in melanoma, and lineage-specific overexpression in gastrointestinal stromal tumors (GIST) (AACR Journals; Nature). Although historically considered "undruggable" due to the lack of a defined enzymatic pocket, therapeutic strategies now include direct small-molecule perturbagens like BRD32048 that promote its degradation and indirect targeting using MEK inhibitors (e.g., Trametinib) to destabilize the protein (Molecular Cancer Therapeutics; Life Raft Group). Clinical interest remains high for ETV1-driven malignancies, where it serves as both a diagnostic biomarker and a potential target for combination therapies (PubMed).

Other names

ER81ETS variant 1ETS variant transcription factor 1Ets-related protein 81Ets variant gene 1

Direct binding and degradation; Inhibition of transcriptional activity; MAPK/MEK pathway inhibition to reduce protein stability